Claire Albrecht

Issy-les-moulineaux, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

European Expert Recommendations on Teclistamab Management for Relapsed or Refractory Multiple Myeloma.

European Expert Recommendations on Teclistamab Management for Relapsed or Refractory Multiple Myeloma.

Journal: Clinical lymphoma, myeloma & leukemia

Published: October 29, 2025

REALiTEC: a multi-country observational retrospective study of teclistamab in patients with relapsed/refractory multiple myeloma outside of clinical trials.

REALiTEC: a multi-country observational retrospective study of teclistamab in patients with relapsed/refractory multiple myeloma outside of clinical trials.

Journal: Haematologica

Published: September 30, 2025

Comparative Efficacy of Talquetamab vs. Real-World Physician's Choice of Treatment in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: Updated Analyses of MonumenTAL-1 vs. LocoMMotion/MoMMent.

Comparative Efficacy of Talquetamab vs. Real-World Physician's Choice of Treatment in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: Updated Analyses of MonumenTAL-1 vs. LocoMMotion/MoMMent.

Journal: Advances in therapy

Published: September 02, 2025

European Expert Panel Consensus on Outpatient Administration of Teclistamab and Talquetamab in Patients With Multiple Myeloma: Feasibility, Key Considerations, and Future Directions.

European Expert Panel Consensus on Outpatient Administration of Teclistamab and Talquetamab in Patients With Multiple Myeloma: Feasibility, Key Considerations, and Future Directions.

Journal: European journal of haematology

Published: March 12, 2025

Outcomes of Patients With Extramedullary Disease in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma From the Pooled LocoMMotion and MoMMent Studies.

Outcomes of Patients With Extramedullary Disease in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma From the Pooled LocoMMotion and MoMMent Studies.

Journal: Clinical lymphoma, myeloma & leukemia

Published: February 03, 2025

Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma.

Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma.

Journal: Advances in therapy

Published: October 11, 2023

Comparative Effectiveness of Teclistamab Versus Real-World Physician's Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma.

Comparative Effectiveness of Teclistamab Versus Real-World Physician's Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma.

Journal: Advances in therapy

Published: October 06, 2023

FIRE Study: Real-World Effectiveness and Safety of Ibrutinib in Clinical Practice in Patients with CLL and MCL.

FIRE Study: Real-World Effectiveness and Safety of Ibrutinib in Clinical Practice in Patients with CLL and MCL.

Journal: Clinical hematology international

Published: December 22, 2021

Real-world results of ibrutinib in relapsed/refractory CLL in France: Early results on a large series of 428 patients.

Real-world results of ibrutinib in relapsed/refractory CLL in France: Early results on a large series of 428 patients.

Journal: American journal of hematology

Published: April 14, 2017

Biased pain reports through vicarious information: A computational approach to investigate the role of uncertainty.

Biased pain reports through vicarious information: A computational approach to investigate the role of uncertainty.

Journal: Cognition

Published: March 07, 2017

Showing 1-10 of 10

Last Updated: 09/26/2026